ArticleMedical science monitor : international medical journal of experimental and clinical research2014
MiR-32 functions as a tumor suppressor and directly targets EZH2 in human oral squamous cell carcinoma.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications.Biomolecules · 2023Review
- Long non-coding RNA SNHG17 contributes to the progression of pancreatic adenocarcinoma by modulating miR-32-5p/EZH2/STAT3 signaling.Molecular biology reports · 2023Article
- lncRNA MALAT1 promotes cell proliferation and invasion by regulating the miR-101/EZH2 axis in oral squamous cell carcinoma.Oncology letters · 2020Article
- MicroRNAs: Diverse Mechanisms of Action and Their Potential Applications as Cancer Epi-Therapeutics.Biomolecules · 2020Review
- MicroRNA Signatures in Blood or Bone Marrow Distinguish Subtypes of Pediatric Acute Lymphoblastic Leukemia.Translational oncology · 2020Article
- MicroRNA-32 promotes ovarian cancer cell proliferation and motility by targeting SMG1.Oncology letters · 2020Article
- AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition.Acta pharmacologica Sinica · 2019Article
- MicroRNA-32 Regulates Development and Progression of Hepatocellular Carcinoma by Targeting ADAMTS9 and Affects Its Prognosis.Medical science monitor basic research · 2018Article
- Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma.Oncology letters · 2018Article
- Downregulation of miR-221/222 by a microRNA sponge promotes apoptosis in oral squamous cell carcinoma cells through upregulation of PTEN.Oncology letters · 2016Article
- Increased Expression of Tissue/Salivary Transgelin mRNA Predicts Poor Prognosis in Patients with Oral Squamous Cell Carcinoma (OSCC).Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Oncotarget · 2015Review
- Deregulation of RGS17 Expression Promotes Breast Cancer Progression.Journal of Cancer · 2015Article
- Grb2-associated binder 2 silencing impairs growth and migration of H1975 cells via modulation of PI3K-Akt signaling.International journal of clinical and experimental pathology · 2015Article
- MiR-32 Inhibits Proliferation and Metastasis by Targeting EZH2 in Glioma.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA-32 (miR-32) is dysregulated in certain human malignancies and correlates with tumor progression. However, its expression and function in oral squamous cell carcinoma (OSCC) remain unclear. Thus, the aim of this study was to explore the effects of miR-32 expression on OSCC tumorigenesis and development. MATERIAL/
methodsReal-time quantitative PCR was applied to evaluate the expression level of miR-32 in OSCC cell lines and primary tumor tissues. The association of miR-32 expression with clinicopathological factors and prognosis was also analyzed. In vitro cell proliferation, apoptosis, invasion, and migration assays were executed to elucidate biological effects of miR-32. Western blotting and luciferase assays were performed to confirm the regulation of EZH2 by miR-32.
resultsDown-regulation of miR-32 was found in OSCC tissues compared with corresponding noncancerous tissues (P<0.001). Decreased miR-32 expression was significantly associated with advanced T classifications, positive N classification, advanced TNM stage, and shorter overall survival (all P<0.05). Multivariate regression analysis corroborated that low-level expression of miR-32 was an independent unfavorable prognostic factor for OSCC patients. In vitro functional assays showed that overexpression of miR-32 reduced OSCC cell proliferation, migration, and invasion, and promoted cell apoptosis. In contrast, miR-32 knock-down resulted in an increase in cell growth and invasiveness. Finally, we identified EZH2 as the functional downstream target of miR-32 by directly targeting the 3'-UTR of EZH2.
conclusionsThese findings indicate that miR-32 may act as a tumor suppressor in OSCC and could serve as a novel therapeutic agent for miR-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.